Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,923 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Leukaemia, Myelocytic, Acute
Interventions: GSK2879552, ATRA; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Augusta, Georgia • New York, New York • The Bronx, New York + 1 more

Conditions: Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions: TRICOM-CEA(6D); Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Neoplasms
Interventions: neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: Primary Biliary Cholangitis
Interventions: APD334; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more

Conditions: HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
Interventions: Nivolumab-IRDye800; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more

Conditions: Head and Neck Cancer
Interventions: biologic sample preservation procedure, biopsy; Other · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 97
States / cities: Birmingham, Alabama • Sacramento, California • Colorado Springs, Colorado + 68 more

Conditions: Autistic Disorder
Interventions: Fluoxetine (prozac); Drug
Lead sponsor: Neuropharm; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more

Conditions: Irritable Bowel Syndrome
Interventions: LX1031 High Dose, LX1031 Low Dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Tucson, Arizona • Sherwood, Arkansas • Anaheim, California + 29 more

Conditions: Bipolar I Disorder
Interventions: Endoxifen, Placebo oral tablet; Drug
Lead sponsor: Jina Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gingivitis, Periodontitis
Interventions: ClōSYS® Sensitive Fluoride Toothpaste, ClōSYS® Sensitive Rinse; Drug · Other
Lead sponsor: Rowpar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis, Gastroparesis Postoperative
Interventions: Gastric Per Oral Endoscopic Myotomy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Uveal Melanoma
Interventions: AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Depressive Disorder, Major
Interventions: BI 1358894, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Toothache
Interventions: Naproxen Sodium ER (BAYH6689), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Austin, Texas • Salt Lake City, Utah

Conditions: Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions: Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: exenatide, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon

Conditions: Gingival Diseases
Interventions: 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Edentulous or Failing Dentition Mandible
Interventions: TREFOIL concept; Device
Lead sponsor: Nobel Biocare; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Crohn's Disease
Interventions: GSK1605786A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more

Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Episodic Migraine
Interventions: Atogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 113
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Conditions: Psoriasis
Interventions: Internet Survey; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 12 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Search by objective public record fields.

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Study Evaluating HKI-272 in Tumors

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer

Extended Management and Measurement of Autism

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP

G-POEM for Treatment of Refractory Gastroparesis

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

Brief Title: a Clinical Study to Assess Gingivitis

The TREFOIL Concept 5 Year Clinical Investigation

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Oral Psoriasis Treatment Adherence and Intervention Study

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis